Contrasting Enanta Pharmaceuticals (NASDAQ:ENTA) & Critical Outcome Technologies (OTCMKTS:COTQF)

Enanta Pharmaceuticals (NASDAQ:ENTA) and Critical Outcome Technologies (OTCMKTS:COTQF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Insider & Institutional Ownership

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Enanta Pharmaceuticals and Critical Outcome Technologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32 million	6.12	-$81.89 million	($2.59)	-5.31
Critical Outcome Technologies	N/A	N/A	N/A	N/A	N/A

Critical Outcome Technologies has lower revenue, but higher earnings than Enanta Pharmaceuticals.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Enanta Pharmaceuticals and Critical Outcome Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1	0	7	0	2.75
Critical Outcome Technologies	0	0	0	0	0.00

Enanta Pharmaceuticals presently has a consensus target price of $20.29, suggesting a potential upside of 47.64%. Given Enanta Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Enanta Pharmaceuticals is more favorable than Critical Outcome Technologies.

Profitability

This table compares Enanta Pharmaceuticals and Critical Outcome Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Critical Outcome Technologies	N/A	N/A	N/A

Summary

Enanta Pharmaceuticals beats Critical Outcome Technologies on 6 of the 9 factors compared between the two stocks.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

About Critical Outcome Technologies

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.